Atlas Trials

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

Clinical trial NCT04187560 · COMPLETED

Trial details

NCT number
NCT04187560
Sponsor
LB Pharmaceuticals Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia
Start date
2020-01-22
Primary completion
2020-07-01
Enrollment
64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.